Abstract
Introduction: The use of biological therapy has been associated with an increased risk for different types of infections. In this sense, the development of strategies for prevention and treatment of infections in patients with rheumatic diseases with biological therapy is essential. Currently there is little information on the seroprevalence of Chagas disease (CD) and toxoplasmosis in patients with rheumatic diseases. Objective: To analyze the seroprevalence of CD and toxoplasmosis in patients with rheumatic diseases in plans to start BT. Methodology: Retrospective study of patients with rheumatic diseases whit criteria to start a BT in the Rheumatology Service of the IPS Central Hospital. Clinical, epidemiological, serological and treatment-related variables were recorded. The frequency of positive serology for CD and toxoplasmosis was analyzed and the association with the collected variables was studied. Results: 228 patients were included (RA = 176, Sp = 43, Collagenopathy = 9), 74.6% were women with a mean age of 46.2 years. Chagas seroprevalence was 2.9% and toxoplasmosis 63.1%. No significant associations were identified with the analyzed variables. Conclusion: The seroprevalence of toxoplasmosis and Chagas disease was similar to that described in studies of the general population of our country and the region, so it is important to always keep them in mind especially in developing countries.1Q In the present study, a reactivation of the disease after the onset of BT was not found.
Highlights
The use of biological therapy has been associated with an increased risk for different types of infections
No significant associations were identified with the analyzed variables
The seroprevalence of toxoplasmosis and Chagas disease was similar to that described in studies of the general population of our country and the region, so it is important to always keep them in mind especially in developing countries.1Q In the present study, a reactivation of the disease after the onset of BT was not found. enthesis involvement in patients with spondyloarthritis
Summary
Seroprevalencia de Chagas y Toxoplasmosis en pacientes con enfermedades Reumatológicas. Es fundamental el desarrollo de estrategias para su prevención y tratamiento en los pacientes con enfermedades reumatológicas tratados con estos agentes. Actualmente existe escasa información sobre la seroprevalencia de la enfermedad de Chagas (EC) y de toxoplasmosis en pacientes con enfermedades reumatológicas. Se consultó el registro BIOBADAGUAY para valorar la evolución clínica de los pacientes posterior al inicio de la TB. Conclusión: La seroprevalencia de toxoplasmosis y EC fue similar a lo descrito en estudios poblacionales de nuestro país y de la región, por lo que deben ser consideradas en pacientes en planes de iniciar un tratamiento inmunosupresor, sobre todo en pacientes originarios de países en vías de desarrollo. En nuestra serie de pacientes, no se ha constatado una reactivación de la enfermedad posterior al inicio de la TB.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
